Testing a new immune-boosting cancer treatment at different dose levels

This Phase 1 trial is testing a new drug called HCB301, which combines three different cancer-fighting approaches to help your immune system recognize and attack cancer cells. The study involves gradually increasing doses of the medication in groups of patients to find the right dose and learn how safe and effective it is. Researchers want to understand how the treatment works, what side effects it causes, and whether it can help people with advanced solid tumors or Hodgkin lymphoma that haven't responded to other therapies.

Many patients with advanced cancers run out of standard treatment options, and their cancers continue to grow. This medication takes a novel approach by combining multiple immune-targeting strategies to overcome the cancer's ability to hide from the immune system, offering hope for patients who have few other options.